169 related articles for article (PubMed ID: 21150235)
21. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
22. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
24. Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system.
Perrella A; Esposito C; Amato G; Perrella O; Migliaccio C; Pisaniello D; Calise F; Cuomo O; Santaniello W
Infect Dis (Lond); 2016 Feb; 48(2):161-6. PubMed ID: 26513601
[TBL] [Abstract][Full Text] [Related]
25. Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation.
Mori T; Nakamura Y; Kato J; Sugita K; Murata M; Kamei K; Okamoto S
Transpl Infect Dis; 2012 Feb; 14(1):91-4. PubMed ID: 21535337
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
[TBL] [Abstract][Full Text] [Related]
27. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Jantunen E; Nihtinen A; Volin L; Juvonen E; Parkkali T; Ruutu T; Anttila VJ
Bone Marrow Transplant; 2004 Nov; 34(10):891-5. PubMed ID: 15517009
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
29. Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.
Jin H; Fan Z; Huang F; Chai Y; Xuan L; Lin R; Xu N; Ye J; Sun J; Liu Q
Infection; 2019 Apr; 47(2):275-284. PubMed ID: 30734248
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey.
Rasheed W; Ghavamzadeh A; Hamladji R; Ben Othman T; Alseraihy A; Abdel-Rahman F; Elhaddad A; Alabdulaaly A; Dennison D; Ibrahim A; Bazarbachi A; Bekadja MA; Mohamed SY; Adil SN; Ahmed P; Benchekroun S; Ramzi M; Jarrar M; Alimoghaddam K; Hussain F; Hamidieh A; Aljurf M
Hematol Oncol Stem Cell Ther; 2013 Mar; 6(1):14-9. PubMed ID: 23664600
[TBL] [Abstract][Full Text] [Related]
31. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
32. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
33. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
34. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
36. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
Yáñez L; Insunza A; Ibarrondo P; de Miguel C; Bermúdez A; Colorado M; López-Duarte M; Richard C; Conde E
Transpl Infect Dis; 2015 Oct; 17(5):761-7. PubMed ID: 26250790
[TBL] [Abstract][Full Text] [Related]
37. Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.
Safdar A; Rodriguez GH
Pharmacotherapy; 2013 Oct; 33(10):1035-43. PubMed ID: 23784915
[TBL] [Abstract][Full Text] [Related]
38. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
39. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
[TBL] [Abstract][Full Text] [Related]
40. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
